The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study

Basit Öğe Kaydı
dc.contributor.authorUgrakli, Muzaffer
dc.contributor.authorKocak, Mehmet Zahid
dc.contributor.authorDinc, Gulhan
dc.contributor.authorGenc, Tugrul Burak
dc.contributor.authorCaglayan, Melek
dc.contributor.authorUgrakli, Selin
dc.contributor.authorHendem, Engin
dc.date.accessioned2024-02-23T13:43:51Z
dc.date.available2024-02-23T13:43:51Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractAimWe aimed to evaluate the effect of concomitant proton pump inhibitors (PPI) use with nivolumab on survival outcomes in metastatic renal cell carcinoma (mRCC) in second-line setting.MethodsThe study was designed as a multicenter and retrospective involving patients with metastatic renal cell carcinoma receiving second-line nivolumab therapy. One hundred and nine patients with mRCC were divided into two groups based on whether they use PPI concomitantly with nivolumab: concomitant PPI users and non-users. Overall survival (OS) and progression-free survival (PFS) were compared between the groups with and without concurrent PPIs.ResultsOf 109 patients in our study, 59 were not using PPI concomitantly with nivolumab and 50 were using PPI concomitantly. The median PFS was 6.37 (5.2-7.5) months in the concomitant PPI group and 9.7 (4.5-15) months in the non-users (p = 0.03). The median OS was 14.6 (7.1-22.1) months in patients on PPI concurrently with nivolumab and 29.9 (17.1-42.7) months in the non-users (p = 0.01). Accordingly, PPI use for PFS (Non-use vs. Use = HR: 0.44, 95%Cl 0.28-0.96, p = 0.014) and PPI use for OS (Non-use vs. Use = HR: 0.68, 95%Cl 0.22-0.88, p = 0.01) were found to be as independent risk factors.ConclusionsConcomitant use of PPIs is associated with worse survival outcomes in patients with mRCC treated with nivolumab. Clinicians should carefully consider the concomitant use of PPIs in such patients.en_US
dc.identifier.doi10.1007/s00432-023-04844-6
dc.identifier.endpage9189en_US
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.issue11en_US
dc.identifier.pmid37184681en_US
dc.identifier.scopus2-s2.0-85159336199en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage9183en_US
dc.identifier.urihttps://doi.org/10.1007/s00432-023-04844-6
dc.identifier.urihttps://hdl.handle.net/20.500.12452/10953
dc.identifier.volume149en_US
dc.identifier.wosWOS:000987953100002en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Cancer Research And Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectNivolumaben_US
dc.subjectProton Pump Inhibitoren_US
dc.subjectSurvivalen_US
dc.titleThe effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu